Literature DB >> 16020917

Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.

Atsuhito Saiki1, Takeyoshi Murano, Fusako Watanabe, Tomokazu Oyama, Yoh Miyashita, Kohji Shirai.   

Abstract

It is known that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) enhance the expression- of the low-density lipoprotein (LDL) receptor and lower the level of LDL cholesterol in the blood. But, a triglyceride (TG)-lowering effect is also observed during their administration. To clarify the possibility that statins enhance LPL activity and its mechanism, the effects of statins on the expression of LPL in adipocytes were studied. When statins (pravastatin, simvastatin, atorvastatin and pitavastatin) were added to the culture medium of mouse 3T3-L1 preadipocytes at final concentrations of 1 microM for 3 days, LPL activity increased. Pitavastatin increased the activity the most. Western and Northern blotting showed that LPL protein and m-RNA were strongly expressed on the addition of pitavastatin. With the addition of mevalonate (10 microM, 3 days), LPL activity weakened significantly. Statins, especially pitavastatin, increased the expression of LPL in 3T3-L1 preadipocytes. The TG-lowering effect of pitavastatin might be mediated by enhancement of LPL production in adipocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020917     DOI: 10.5551/jat.12.163

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  13 in total

1.  Accurate evaluation of relationships among serum lipoprotein lipase mass, visceral fat, and retinal nerve fiber layer thickness.

Authors:  Tomoaki Shiba; Mao Takahashi; Chieko Shiba; Yuichi Hori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-08       Impact factor: 3.117

2.  Relationships among serum lipoprotein lipase mass, visceral fat, and retinal nerve fiber layer thickness.

Authors:  Chieko Shiba; Tomoaki Shiba; Mao Takahashi; Yuichi Hori; Takatoshi Maeno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-31       Impact factor: 3.117

3.  Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

Authors:  B Vergès; E Florentin; S Baillot-Rudoni; S Monier; J M Petit; D Rageot; P Gambert; L Duvillard
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

4.  Lipoprotein lipase HindIII polymorphism influences HDL-cholesterol levels in statin-treated patients with coronary artery disease.

Authors:  Martin Javorský; Daniela Gasperíková; Jozef Ukropec; Barbora Sedláková; Igor Riecanský; Ol'ga Krizanová; Elena Seböková; Martina Dobríková; Iwar Klimes; Ivan Tkác
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 5.  Benefits of statin therapy and compliance in high risk cardiovascular patients.

Authors:  Joel A Lardizabal; Prakash C Deedwania
Journal:  Vasc Health Risk Manag       Date:  2010-10-05

Review 6.  The anti-ischemic and anti-anginal properties of statins.

Authors:  Joel A Lardizabal; Prakash C Deedwania
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

7.  Short-term effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men.

Authors:  Hirokazu Kakuda; Junji Kobayashi; Mio Nakato; Noboru Takekoshi
Journal:  Cholesterol       Date:  2013-12-10

8.  Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).

Authors:  Ping-Yen Liu; Liang-Yu Lin; Hung-Ju Lin; Chien-Hsun Hsia; Yi-Ren Hung; Hung-I Yeh; Tao-Cheng Wu; Ju-Yi Chen; Kuo-Liong Chien; Jaw-Wen Chen
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

9.  Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells.

Authors:  Makoto Seo; Ikuo Inoue; Masaaki Ikeda; Takanari Nakano; Seiichiro Takahashi; Shigehiro Katayama; Tsugikazu Komoda
Journal:  PPAR Res       Date:  2008-12-24       Impact factor: 4.964

10.  Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes.

Authors:  Chung-Huei Huang; Yu-Yao Huang; Brend Ray-Sea Hsu
Journal:  J Diabetes Investig       Date:  2016-02-22       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.